Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00839436
Recruitment Status :
(Bankruptcy of Drug manufacturer: Drug not available)
First Posted : February 9, 2009
Results First Posted : October 15, 2015
Last Update Posted : October 15, 2015
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
Idiopathic CD4 lymphocytopenia (ICL) is a condition in which patients have low levels of T cells, a type of white blood cell that helps fight infection. Animal studies have shown that an experimental drug Interleukin 7 (IL-7), which is named CYT107, can increase the number and function of T cells. CYT107, however, has not been used in people with ICL.
To determine the safety of CYT107 in people with ICL.
To determine whether CYT107 will increase the number and function of T cells in people with ICL.
Patients 18 years of age and older diagnosed with ICL and who are at risk of becoming sick because of this condition are eligible for this study. In addition, patients must not be pregnant, or have other illnesses that would cause low CD4 T cell counts, such as human immunodeficiency virus (HIV) or human T-lymphotrophic virus (HTLV) infection.
The initial screening visit will include the following examinations and tests:
A complete physical exam and medical history
Blood analysis, including CD4 T cell count; complete blood count and additional blood tests to determine clotting ability and blood composition; thyroid, liver, kidney, and pancreatic function tests; HIV and HTLV tests; and tests for anti-IL-7 antibodies that block normal IL-7 activity
Routine urine test
Urine or blood pregnancy test for women
The baseline visit will include blood tests to determine levels of each of the major types of antibodies, a test of genetic background, and more detailed CD4 and protein analysis. In addition, leukapheresis (a procedure to collect large numbers of immune cells without red blood cells) will be done. Participants will also have the option of having colon and lymph node biopsies.
The schedule will be as follows:
Weeks 1, 2, and 3 (Cycle 1): Three weekly IL-7 dosing visits.
Weeks 5, 8, and 12: Follow-up visits.
Weeks 24, 25, and 26 (Cycle 2): Three more weekly IL-7 dosing visits.
Weeks 28, 31, and 35: Follow-up visits.
Week 48: End of study visit.
Tests conducted before getting IL-7 will be repeated during the IL-7 cycles and follow-up visits to compare with earlier values. Optional colon and lymph node biopsies done at baseline will be repeated 1 6 weeks prior to Cycle 2 and 1 6 weeks prior to Week 48.
Adverse Events and Toxicities Associated With CYT107. [ Time Frame: 48 weeks per patient with a 3-4 year enrollment period ]
Other Outcome Measures:
Change: CD4/CD8 T Cell Cts After CYT107; in Immunophenotype (Naive, Memory, Regulatory T Cell Subsets) & Amp; Antigen-specific T Cell Function After CYT107; in T Cell Activation/Proliferation Status & Amp; TCR Repertoire After CYT107; ... [ Time Frame: 48 weeks per patient with a 3-4 year enrollment period ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age greater than or equal to 18 years
CD4 T cell count less than 300 cells/microL or less than 20% of total T lymphocytes on 2 occasions at least 6 weeks apart (and at the time of screening) in the absence of any illness accounting for CD4 lymphocytopenia
ICL diagnosis that indicates a risk for disease progression, defined as one or both of the following:
CD8 T cell lymphocytopenia (less than 180 cells/microL)
History of opportunistic or otherwise significant infection (e.g., AIDS-defining or highly morbid illnesses, such as Cryptococcus or Mycobacteria infection, severe herpes zoster, JC virus causing progressive multifocal leukoencephalopathy, Kaposi s sarcoma, or severe human papilloma virus condylomata)
HIV-1 and HIV-2 seronegativity and below detection of HIV-1 viral load
HTLV-1 and HTLV-2 seronegativity
Adequate venous access, as determined by the study team, although participants unable to undergo leukapheresis will not be excluded
Normal thyroid-stimulating hormone (TSH)
Negative serum or urine pregnancy test at time of study enrollment for women of childbearing potential
Ability to understand and give informed consent
Capacity and willingness to adhere to study procedures, including scheduled follow-up visits
Willingness to allow blood and tissue sample storage
Established primary care provider
History of prior cytotoxic, chemotherapeutic, immunosuppressant (e.g., systemic corticosteroids), immunomodulatory (e.g., IL-2, IL-7, interferon-gama), or growth factor therapy within the last 6 months; chemotherapy or immunomodulatory therapy given to treat an underlying disease or condition may be permitted at the protocol team's discretion, provided diagnosis of ICL was established prior to starting this treatment. The treatment has been stable for over 6 months and is being administered at stable doses as maintenance therapy.
History of prior participation in another investigational intervention study within the last 6 months. Co-enrollment in other NIAID stem cell mobilization protocols will be permitted at the protocol team s discretion, but CYT107 may be dosed no sooner than 6 months after last dose of that protocol s medications have been given.
Active uncontrolled opportunistic infection at the time of enrollment
Current or recent history (less than 28 days prior to screening) of a viral, bacterial, parasitic or fungal infection requiring hospitalization and/or systemic treatment, other than long-term maintenance pharmacotherapy
Serious illness requiring systemic treatment and/or hospitalization within 56 days (8 weeks) of screening, unless the subject is clinically stable, in the opinion of the Principal Investigator, and has completed therapy or has been on appropriate therapy for greater than 28 days (4 weeks) prior to screening
Current or history of hematologic or lymphoid (lymphoma) malignancy
Established or planned pregnancies or refusal to use effective birth control (e.g., barrier methods, oral contraceptives, intrauterine devices) for the duration of study involvement, regardless of gender
Renal insufficiency (e.g., estimated glomerular filtration rate less than 60 mL/min/1.73 m(2))
Any of the following screening laboratory abnormalities: platelets less than 100,000 cells/microL; lipase greater than 1.5 times the ULN; AST, ALT, or alkaline phosphatase greater than 2.5 times the ULN; total bilirubin greater than 1.5 times the ULN
History of splenectomy or hematologic disease associated with hypersplenism, such as alpha- or beta-thalassemia, hereditary spherocytosis, Gaucher s disease, or autoimmune hemolytic anemia
Cirrhosis of any origin, including alcoholic or non-alcoholic steatohepatitis, either suspected by history or histologically proven
History of hepatitis B or C infection, i.e., positive hepatitis B surface antigen, positive anti-hepatitis B core antibody with a detectable hepatitis B DNA viral load, positive anti-hepatitis C antibody and/or detectable hepatitis C RNA viral load (subjects who became negative for hepatitis B DNA or hepatitis C RNA following anti-viral treatment will not qualify for study treatment)
Need for anticoagulant medication (e.g., warfarin, heparin), other than aspirin, clopidogrel, or other antiplatelet agent as CYT107 may co-precipitate with heparin if taken together.
Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements (subjects must agree to refrain from substance abuse use during the entire course of the study)
Past or current psychiatric illness that, in the opinion of the investigator, would interfere with protocol adherence or the ability and willingness to give written informed consent
Current autoimmune conditions requiring systemic (oral, injection, or other parenteral) therapy, as well as psoriasis and optic neuritis regardless of treatment and/or a diagnosis of systemic lupus erythematous based on the screening rheumatologic work up.
Cardiac, pulmonary, thyroid, renal, hepatic, neurological (central or peripheral) disease or disorder of hemostasis requiring therapy and considered to be significant by the protocol team
History of cardiovascular disease, arrhythmias, or clinically significant ECG abnormalities, including a corrected QT interval (QTc) greater than or equal to 470 milliseconds
Family history consistent with an inherited cardiomyopathy or arrhythmia such as the following:
Arrhythmogenic Right Ventricular Dysplasia (ARVD)
Brugada syndrome (BrS)
Congenital Long QT (LQT)
Congenital Short QT intervals (SQT)
Early Repolarization Syndrome
Idiopathic Ventricular Fibrillation (IVF)
Uncontrolled hypertension (i.e., resting systolic blood pressure greater than160 mmHg or resting diastolic blood pressure greater than 90 mmHg), despite pharmacologic antihypertensive treatment, confirmed with a second blood pressure measurement done later in the same day.
Evidence of circulating neutralizing anti-IL-7 antibodies (prior to initial rhIL-7 administration)
To be eligible for rhIL-7 administration, all Exclusion Criteria are prohibited. However, for the purpose of performing baseine pre-IL-7 procedures certain Exclusion Criteria designed to minimize specific complications from rhIL-7 (e.g., autoimmune or lymphoproliferative complications) but that do not increase the risk associated with these procedures are permitted, as baseline procedures will be done prior to IL-7 administration: #6, #11, through #13, #17, #18, #20, #22.